Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States

Overview of attention for article published in Frontiers in Pharmacology, March 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,909 followers.

RT @FrontPharmacol: New Research: Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness an…

28 Mar 2024

Reply Repost Favourite

New Research: Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States https://t.co/Fc5uaBJlvy #pharmacology

28 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.